Drug Profile
HDP 990007
Latest Information Update: 13 Oct 2017
Price :
$50
*
At a glance
- Originator Heidelberg Pharma
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
- 31 May 2005 Discontinued - Preclinical for Solid tumours in Germany (PO)
- 05 Jul 2004 This compound is still in active development - BIO 2004 Annual International Convention (BIO-2004)